Patients ( n = @ ) in the abagovomab arm without CA@-specific CTL but that developed Ab@ above the cutoff ( defined as median Ab@ level at week @ ) had a prolonged RFS compared to patients ( n = @ ) that did not develop Ab@ above the cutoff ( log-rank test p = @ ) .